DYAI Stock Overview
A biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Dyadic International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.54 |
| 52 Week High | US$2.67 |
| 52 Week Low | US$0.93 |
| Beta | 0.89 |
| 1 Month Change | -11.49% |
| 3 Month Change | 45.28% |
| 1 Year Change | 6.21% |
| 3 Year Change | -57.22% |
| 5 Year Change | -72.70% |
| Change since IPO | -75.36% |
Recent News & Updates
Recent updates
Does Dyadic International (NASDAQ:DYAI) Have A Healthy Balance Sheet?
Jul 17
Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?
Mar 14Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?
Oct 28Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation
Jun 21We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely
Oct 05Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate
May 26We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate
May 03Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth
Feb 22Dyadic International (NASDAQ:DYAI) Is In A Good Position To Deliver On Growth Plans
Jan 18
Do Insiders Own Lots Of Shares In Dyadic International, Inc. (NASDAQ:DYAI)?
Dec 10Dyadic International reports Q3 results
Nov 12Shareholder Returns
| DYAI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.4% | 4.7% | 3.0% |
| 1Y | 6.2% | -3.1% | 25.2% |
Return vs Industry: DYAI exceeded the US Biotechs industry which returned -4.1% over the past year.
Return vs Market: DYAI underperformed the US Market which returned 25% over the past year.
Price Volatility
| DYAI volatility | |
|---|---|
| DYAI Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: DYAI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DYAI's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 7 | Mark Emalfarb | www.dyadic.com |
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform.
Dyadic International, Inc. Fundamentals Summary
| DYAI fundamental statistics | |
|---|---|
| Market cap | US$46.16m |
| Earnings (TTM) | -US$6.33m |
| Revenue (TTM) | US$3.36m |
13.5x
P/S Ratio-7.2x
P/E RatioIs DYAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DYAI income statement (TTM) | |
|---|---|
| Revenue | US$3.36m |
| Cost of Revenue | US$1.19m |
| Gross Profit | US$2.17m |
| Other Expenses | US$8.50m |
| Earnings | -US$6.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 64.57% |
| Net Profit Margin | -188.14% |
| Debt/Equity Ratio | 154.4% |
How did DYAI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 23:36 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dyadic International, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vernon Bernardino | H.C. Wainwright & Co. |
| John Vandermosten | Zacks Small-Cap Research |